Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
JAMA Network Open|May 9, 2022
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 VaccineKoichi Furukawa, Lidya Handayani Tjan, Yukiya Kurahashi, et al.Journal of Infection and Public Health|May 17, 2023
Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly populationSilvia Sutandhio, Koichi Furukawa, Yukiya Kurahashi, et al.Open Forum Infectious Diseases|October 11, 2021
Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in JapanKoichi Furukawa, Lidya Handayani Tjan, Silvia Sutandhio, et al.Frontiers in Immunology|March 14, 2022
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After InfectionsYukiya Kurahashi, Silvia Sutandhio, Koichi Furukawa, et al.The Journal of Infectious Diseases|May 5, 2022
Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA VaccinationYukiya Kurahashi, Koichi Furukawa, Silvia Sutandhio, et al.Plos One|April 5, 2022
Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreakZhenxiao Ren, Mitsuhiro Nishimura, Lidya Handayani Tjan, et al.Journal of Virology|May 16, 2023
Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 VariantsHanako Ishimaru, Mitsuhiro Nishimura, Lidya Handayani Tjan, et al.JMA Journal|February 12, 2021
Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, JapanKoichi Furukawa, Jun Arii, Mitsuhiro Nishimura, et al.Pageof 1